Royal Philips today reports sales of EUR 4.3 billion for April-June 2018, with 4% comparable sales growth. The net income from continuing operations was EUR 186 million,

Second-quarter highlights:
– Sales in the quarter were EUR 4.3 billion, with comparable sales growth of 4%
– Comparable order intake increased 9% compared to Q2 2017
– Net income from continuing operations was EUR 186 million, compared to EUR 161 million in Q2 2017
– Operating cash flow totaled EUR 130 million, compared to EUR 73 million in Q2 2017

Philips focuses on health care solutions. Frans van Houten, CEO, is looking back on some major deals in the second quarter and expects continued growth in the next years:

Subscribe to IO on Telegram!

Want to be inspired 365 days per year? Here’s the opportunity. We offer you one "origin of innovation" a day in a compact Telegram message. Seven days a week, delivered around 8 p.m. CET. Straight from our newsroom. Subscribe here, it's free!

Subscribe!

“I am pleased with the continued strong performance improvement of the Diagnosis & Treatment businesses, driven by the breadth of our innovative product portfolio, which resulted in 8% comparable sales growth and double-digit order intake growth. At the same time, I am encouraged by the mid-single-digit order intake growth of the Connected Care & Health Informatics businesses. After a slow start, the Personal Health businesses gained momentum in the quarter, and we expect this to continue in the second half of the year.

Demonstrating our ongoing success in building our solutions business, we signed seven long-term strategic partnership agreements in the quarter. In Germany, Philips announced two multi-year agreements with Clinics of Cologne and Munich Municipal Hospital to deliver medical imaging solutions to support precision diagnosis and therapy, innovation and productivity improvements. We also signed a seven-year agreement with the governments of the Netherlands and Ethiopia to design, build and equip Ethiopia’s first specialized Cardiac Care Center for state-of-the-art diagnosis and treatment of cardiac diseases.

Looking ahead, we reiterate our targets for the 2017–2020 period of 4-6% comparable sales growth and an average annual 100 basis points improvement in Adjusted EBITA margin.”

Support us!

Innovation Origins is an independent news platform that has an unconventional revenue model. We are sponsored by companies that support our mission: to spread the story of innovation. Read more.

At Innovation Origins, you can always read our articles for free. We want to keep it that way. Have you enjoyed our articles so much that you want support our mission? Then use the button below:

Doneer

Personal Info

About the author

Author profile picture